Clinical Trial Update: Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection [Phase 2]

View source ↗

Summary

Phase 2 trial of inhaled molgramostim in cystic fibrosis patients with non-tuberculous mycobacterial infection was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Mycobacterium Infections Nontuberculous

Drugs mentioned

• Molgramostim (granulocyte-macrophage colony-stimulating factor (GM-CSF))

Snippet

Sponsor: Savara Inc. | Conditions: Mycobacterium Infections, Nontuberculous, Cystic Fibrosis (CF) | Phase 2 | Status: TERMINATED | Results posted: 2021-10-11